Opus Point Partners Management as of Sept. 30, 2018
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 47 positions in its portfolio as reported in the September 2018 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Tesaro | 8.8 | $3.7M | 94k | 39.01 | |
Proqr Thrapeutics N V shs euro (PRQR) | 6.4 | $2.7M | 139k | 19.35 | |
Clovis Oncology | 5.8 | $2.4M | 82k | 29.37 | |
Mettler-Toledo International (MTD) | 4.7 | $2.0M | 3.2k | 608.96 | |
Illumina (ILMN) | 4.4 | $1.8M | 5.0k | 367.06 | |
Alexion Pharmaceuticals | 4.3 | $1.8M | 13k | 139.02 | |
Vertex Pharmaceuticals Incorporated (VRTX) | 4.0 | $1.7M | 8.7k | 192.74 | |
Mei Pharma | 3.7 | $1.6M | 360k | 4.31 | |
Seattle Genetics | 3.5 | $1.5M | 19k | 77.09 | |
Ionis Pharmaceuticals (IONS) | 2.9 | $1.2M | 23k | 51.56 | |
Qiagen Nv (QGEN) | 2.9 | $1.2M | 32k | 37.89 | |
Alnylam Pharmaceuticals (ALNY) | 2.8 | $1.2M | 14k | 87.49 | |
Agios Pharmaceuticals (AGIO) | 2.8 | $1.2M | 15k | 77.14 | |
Achillion Pharmaceuticals | 2.7 | $1.1M | 309k | 3.68 | |
Alkermes (ALKS) | 2.6 | $1.1M | 25k | 42.43 | |
Loxo Oncology | 2.5 | $1.1M | 6.2k | 170.85 | |
Fibrogen (FGEN) | 2.5 | $1.0M | 17k | 60.74 | |
Regeneron Pharmaceuticals (REGN) | 2.4 | $1.0M | 2.5k | 404.19 | |
BioMarin Pharmaceutical (BMRN) | 2.3 | $956k | 9.9k | 97.02 | |
Adamas Pharmaceuticals | 2.1 | $891k | 45k | 20.02 | |
Celgene Corporation | 2.1 | $872k | 9.7k | 89.46 | |
Incyte Corporation (INCY) | 2.0 | $853k | 12k | 69.10 | |
Nektar Therapeutics (NKTR) | 1.7 | $720k | 12k | 61.00 | |
Pacira Pharmaceuticals (PCRX) | 1.3 | $553k | 11k | 49.16 | |
Intercept Pharmaceuticals In | 1.2 | $505k | 4.0k | 126.31 | |
Ultragenyx Pharmaceutical (RARE) | 1.1 | $468k | 6.1k | 76.30 | |
Bio-techne Corporation (TECH) | 1.1 | $458k | 2.2k | 204.28 | |
ACADIA Pharmaceuticals (ACAD) | 1.0 | $432k | 21k | 20.74 | |
Neurocrine Biosciences (NBIX) | 1.0 | $417k | 3.4k | 122.97 | |
Axsome Therapeutics (AXSM) | 1.0 | $415k | 120k | 3.45 | |
Intrexon | 1.0 | $409k | 24k | 17.20 | |
Iqvia Holdings (IQV) | 1.0 | $409k | 3.2k | 129.59 | |
Checkpoint Therapeutics | 1.0 | $404k | 113k | 3.58 | |
Akebia Therapeutics (AKBA) | 0.9 | $397k | 45k | 8.82 | |
Charles River Laboratories (CRL) | 0.9 | $380k | 2.8k | 134.47 | |
Amgen (AMGN) | 0.9 | $382k | 1.8k | 207.50 | |
Fortress Biotech | 0.9 | $374k | 234k | 1.60 | |
Biogen Idec (BIIB) | 0.9 | $365k | 1.0k | 353.68 | |
United Therapeutics Corporation (UTHR) | 0.9 | $359k | 2.8k | 127.99 | |
Gilead Sciences (GILD) | 0.8 | $350k | 4.5k | 77.21 | |
Grifols S A Sponsored Adr R (GRFS) | 0.8 | $351k | 16k | 21.34 | |
Exelixis (EXEL) | 0.7 | $292k | 17k | 17.72 | |
Bluebird Bio (BLUE) | 0.7 | $284k | 1.9k | 146.02 | |
Paratek Pharmaceuticals | 0.4 | $175k | 18k | 9.72 | |
Contrafect | 0.3 | $140k | 68k | 2.07 | |
Recro Pharma (SCTL) | 0.2 | $81k | 11k | 7.13 | |
Scynexis | 0.1 | $36k | 30k | 1.20 |